Bone metabolism in children with asthmatreated with inhaled beclomethasone dipropionate

Peter König, Laura Hillman, Cecilia Cervantes, Clive Levine, Christopher Maloney, Barbara Douglass, Linda Johnson, Susan Allen

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Previous studies have shown that inhaled corticosteroids can affect bone metabolismin adults. A study to assess the effect of inhaled beclomethasone, 300 to 800 μg/day for at least 6 months (mean 25 months), was therefore undertaken in children. In part 1 of the study, 18 children with asthma, aged 4 to 17 years (mean 10.1 years), were compared with an age- and sex-matched group of children with asthma not treated with corticosterolds. In part 2, eight more pairs were compared. Comparisons were also made with 61 healthy children. Bone mineral density measured by radiographic absorptiometry, and bone mienral content measured by single-photon absorptiometry and by dual-energy x-ray absorptiometry, showed no significant differences. Serum levels of calcium, magnesium, zinc, total alkaline phosphatase, bone specific alkaline phosphatase, parathyroid hormone, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D also showed no differences. The activity of tartrate-resistant acid phosphatase, a marker of bone resorption, was significantly lower in the beclomethasone group than in both the asthma control and the normal control groups, but urine calcium excretion did not differ. Patients with asthma had lower serum osteocalcin and higher serum copper levels than control subjects without asthma, but treatment with beclomethasone did not affect these values. We conclude that inhaled beclomethasone (up to 800 μg/day) does not reduce bone mineralization or increase bone resorption. Effects on bone formation were difficult to assess because asthma per se caused a significant reduction in osteocalcin, a sensitive marker of bone formation.

Original languageEnglish (US)
Pages (from-to)219-226
Number of pages8
JournalJournal of Pediatrics
Volume122
Issue number2
DOIs
StatePublished - Jan 1 1993

Fingerprint

Beclomethasone
Asthma
Bone and Bones
Osteocalcin
Bone Resorption
Osteogenesis
Alkaline Phosphatase
Serum
Calcium
Physiologic Calcification
Photon Absorptiometry
Parathyroid Hormone
Bone Density
Magnesium
Zinc
Copper
Adrenal Cortex Hormones
Research Design
X-Rays
Urine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Bone metabolism in children with asthmatreated with inhaled beclomethasone dipropionate. / König, Peter; Hillman, Laura; Cervantes, Cecilia; Levine, Clive; Maloney, Christopher; Douglass, Barbara; Johnson, Linda; Allen, Susan.

In: Journal of Pediatrics, Vol. 122, No. 2, 01.01.1993, p. 219-226.

Research output: Contribution to journalArticle

König, P, Hillman, L, Cervantes, C, Levine, C, Maloney, C, Douglass, B, Johnson, L & Allen, S 1993, 'Bone metabolism in children with asthmatreated with inhaled beclomethasone dipropionate', Journal of Pediatrics, vol. 122, no. 2, pp. 219-226. https://doi.org/10.1016/S0022-3476(06)80116-2
König, Peter ; Hillman, Laura ; Cervantes, Cecilia ; Levine, Clive ; Maloney, Christopher ; Douglass, Barbara ; Johnson, Linda ; Allen, Susan. / Bone metabolism in children with asthmatreated with inhaled beclomethasone dipropionate. In: Journal of Pediatrics. 1993 ; Vol. 122, No. 2. pp. 219-226.
@article{d8b2892c008f429d838c9987e912eca1,
title = "Bone metabolism in children with asthmatreated with inhaled beclomethasone dipropionate",
abstract = "Previous studies have shown that inhaled corticosteroids can affect bone metabolismin adults. A study to assess the effect of inhaled beclomethasone, 300 to 800 μg/day for at least 6 months (mean 25 months), was therefore undertaken in children. In part 1 of the study, 18 children with asthma, aged 4 to 17 years (mean 10.1 years), were compared with an age- and sex-matched group of children with asthma not treated with corticosterolds. In part 2, eight more pairs were compared. Comparisons were also made with 61 healthy children. Bone mineral density measured by radiographic absorptiometry, and bone mienral content measured by single-photon absorptiometry and by dual-energy x-ray absorptiometry, showed no significant differences. Serum levels of calcium, magnesium, zinc, total alkaline phosphatase, bone specific alkaline phosphatase, parathyroid hormone, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D also showed no differences. The activity of tartrate-resistant acid phosphatase, a marker of bone resorption, was significantly lower in the beclomethasone group than in both the asthma control and the normal control groups, but urine calcium excretion did not differ. Patients with asthma had lower serum osteocalcin and higher serum copper levels than control subjects without asthma, but treatment with beclomethasone did not affect these values. We conclude that inhaled beclomethasone (up to 800 μg/day) does not reduce bone mineralization or increase bone resorption. Effects on bone formation were difficult to assess because asthma per se caused a significant reduction in osteocalcin, a sensitive marker of bone formation.",
author = "Peter K{\"o}nig and Laura Hillman and Cecilia Cervantes and Clive Levine and Christopher Maloney and Barbara Douglass and Linda Johnson and Susan Allen",
year = "1993",
month = "1",
day = "1",
doi = "10.1016/S0022-3476(06)80116-2",
language = "English (US)",
volume = "122",
pages = "219--226",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Bone metabolism in children with asthmatreated with inhaled beclomethasone dipropionate

AU - König, Peter

AU - Hillman, Laura

AU - Cervantes, Cecilia

AU - Levine, Clive

AU - Maloney, Christopher

AU - Douglass, Barbara

AU - Johnson, Linda

AU - Allen, Susan

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Previous studies have shown that inhaled corticosteroids can affect bone metabolismin adults. A study to assess the effect of inhaled beclomethasone, 300 to 800 μg/day for at least 6 months (mean 25 months), was therefore undertaken in children. In part 1 of the study, 18 children with asthma, aged 4 to 17 years (mean 10.1 years), were compared with an age- and sex-matched group of children with asthma not treated with corticosterolds. In part 2, eight more pairs were compared. Comparisons were also made with 61 healthy children. Bone mineral density measured by radiographic absorptiometry, and bone mienral content measured by single-photon absorptiometry and by dual-energy x-ray absorptiometry, showed no significant differences. Serum levels of calcium, magnesium, zinc, total alkaline phosphatase, bone specific alkaline phosphatase, parathyroid hormone, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D also showed no differences. The activity of tartrate-resistant acid phosphatase, a marker of bone resorption, was significantly lower in the beclomethasone group than in both the asthma control and the normal control groups, but urine calcium excretion did not differ. Patients with asthma had lower serum osteocalcin and higher serum copper levels than control subjects without asthma, but treatment with beclomethasone did not affect these values. We conclude that inhaled beclomethasone (up to 800 μg/day) does not reduce bone mineralization or increase bone resorption. Effects on bone formation were difficult to assess because asthma per se caused a significant reduction in osteocalcin, a sensitive marker of bone formation.

AB - Previous studies have shown that inhaled corticosteroids can affect bone metabolismin adults. A study to assess the effect of inhaled beclomethasone, 300 to 800 μg/day for at least 6 months (mean 25 months), was therefore undertaken in children. In part 1 of the study, 18 children with asthma, aged 4 to 17 years (mean 10.1 years), were compared with an age- and sex-matched group of children with asthma not treated with corticosterolds. In part 2, eight more pairs were compared. Comparisons were also made with 61 healthy children. Bone mineral density measured by radiographic absorptiometry, and bone mienral content measured by single-photon absorptiometry and by dual-energy x-ray absorptiometry, showed no significant differences. Serum levels of calcium, magnesium, zinc, total alkaline phosphatase, bone specific alkaline phosphatase, parathyroid hormone, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D also showed no differences. The activity of tartrate-resistant acid phosphatase, a marker of bone resorption, was significantly lower in the beclomethasone group than in both the asthma control and the normal control groups, but urine calcium excretion did not differ. Patients with asthma had lower serum osteocalcin and higher serum copper levels than control subjects without asthma, but treatment with beclomethasone did not affect these values. We conclude that inhaled beclomethasone (up to 800 μg/day) does not reduce bone mineralization or increase bone resorption. Effects on bone formation were difficult to assess because asthma per se caused a significant reduction in osteocalcin, a sensitive marker of bone formation.

UR - http://www.scopus.com/inward/record.url?scp=0027518481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027518481&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(06)80116-2

DO - 10.1016/S0022-3476(06)80116-2

M3 - Article

C2 - 8429434

AN - SCOPUS:0027518481

VL - 122

SP - 219

EP - 226

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 2

ER -